Dr. McCreary is a neuropsychopharmacologist, with a recognized track record in drug discovery of novel antiparkinsonian and antipsychotic agents. He has strong industrial experience and is currently neurochemistry and pharmacokinetics Project Leader.

Collaboration: action of serotonin 5-HT1A agonists in models of Parkinson’s disease

https://neurolixis-com.mon.world/nl.linkedin.com/pub/andrew-mccreary/4/440/805

Brains Online, Groningen, Pays Bas

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: